An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

The purpose of this study is to compare the usual treatment for Non-Small Cell Lung Cancer (osimertinib) to a combination therapy (osimertinib plus ramucirumab). The combination therapy arm is testing if ramucirumab can help osimertinib control the abnormal EGRG protein for a longer time and keep the disease inactive longer. EGRF protein typically helps the cell grow and divide and some subjects with Non- Small Cell Lung Cancer (NSCLC) have too much of this protein causing the cancer to grow faster. Osimertinib is an FDA approved drug that helps shrink the tumor by blocking the EGRF protein. This study has two arms, and subjects will be assigned randomly. One arm will receive Osimertinib by mouth and the other arm will receive Osimertinib by mouth along with ramucirumab intravenously (through an IV).

Are you Eligible? (Inclusion Criteria)

• Are you at least 18 years old?
• Do you have confirmed non-squamous, non-small cell lung cancer?
• Are you able to take pills by mouth?